SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to recent achievements and potential catalysts, including the registration of their Midnight aircraft with the FAA. Community members are actively discussing the company's prospects, particularly its relationship with Japan Airlines and potential military applications, while also debating whether the stock can outperform its competitor, Joby Aviation. Some investors believe upcoming events, like piloted VTOL flights and air shows, could trigger a significant price increase.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors grapple with recent price action, despite strong earnings, and debate whether the company is oversold or poised for further declines. Community discussions revolve around concerns about capital expenditures and AI investments, while some anticipate a rebound. Others point to potential catalysts like a Gemini partnership or the trial decision, as well as competition from Apple in AI glasses.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, encapsulated by the phrase "Like Bitcoin But Way Higher". Active discussions involve the project's roadmap and potential, with community members emphasizing its cultural relevance and potential for growth, particularly regarding developments in the broader cannabis industry.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as the stock experiences a significant sell-off, sparking debates among investors about potential causes, including a Bloomberg article referencing a competitor's GLP-1 product offering. The community is actively discussing whether the sell-off is an overreaction and if the company's fundamentals remain strong, while also eyeing potential bounce-back opportunities. Some traders speculate about algo manipulation and stop-loss triggers amidst the volatility.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to a sharp decline in its stock price, sparking community concern and speculation about the reasons behind it, including the potential impact of the DVLT deal and the company's leadership. Some investors are questioning the company's direction, while others are anticipating a potential short squeeze or positive news to reverse the current trend. Discussions also involve the possibility of a strategic play related to Semnur and its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's  What You Should Know

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan...

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

Monopar Therapeutics Inc. ($MNPR)Shares of Monopar skyrocketed over 350% by mid-day Thursday after the Wilmette, Illinois-based micro-cap biotech announced an agreement with AstraZeneca plc’s ($AZN) Alexion rare disease subsidiary to exclusively in-license the latter’s ALXN-1840.&nbsp;The drug candidate is a Phase 3 asset and is being investigated for treating Wilson disease, a&nbsp; rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised.&nbsp;The agreement calls upon Monopar paying an upfront cash payment and giving AstraZeneca an equity stake. The smaller biotech is also required to make regulatory and sales milestones-based future payments and royalties on future net sales.<figure class="image"><a href="https://stocktwits.com/symbol/MNPR"><img style="aspect-ratio:628/148;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/mnpr_sentiment_224afae297.png" alt="mnpr-sentiment.png" width="628" height="148"></a><figcaption>MNPR sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>Monopar said it will be responsible for all future development and commercialization activities.&nbsp;Energy Vault Holdings, Inc. ($NRGV)Retail sentiment toward Westlake Village, California-based Energy Vault contrasted the stock move on Thursday. The stock was down over 7% by mid-Thursday despite the lack of any major catalyst.&nbsp;On Monday, Energy Vault, a sustainable, grid-scale energy storage solutions provider, announced an agreement with Australian energy developer Enervest Group for the deployment of a 1,000 MWh battery energy storage in New South Wales, Australia.&nbsp;The stock jumped 25% over the next two sessions before pulling back.<figure class="image"><a href="https://stocktwits.com/symbol/NRGV"><img style="aspect-ratio:638/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nrgv_sentiment_ad5ef0470a.png" alt="nrgv-sentiment.png" width="638" height="147"></a><figcaption>&nbsp;NRGV sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘extremely bullish’ (97/100) compared to the ‘neutral’ sentiment that prevailed on Wednesday.FREYR Battery, Inc. ($FREY)Luxembourg-headquartered FREYR, which manufactures lithium-ion batteries in its Norwegian facilities, has also found traction with retail investors.&nbsp;The green-energy company’s stock may have received a lift from the news that the European Union Innovation Fund has agreed to award 122 million-euro ($132.05 million) to develop its potential joint venture ‘Cathode Active Material’ manufacturing project in Vaasa, Finland.<figure class="image"><a href="https://stocktwits.com/symbol/FREY"><img style="aspect-ratio:637/145;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/frey_sentiment_6c4bdbd8f7.png" alt="frey-sentiment.png" width="637" height="145"></a><figcaption>FREY sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The retail mood is exceedingly exuberant, with the sentiment score on Stocktwits at 97/100.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/quantumscape-stock-jumps-on-earnings-call-updates/cJ21uofR7Z">QuantumScape Stock Bounces Back After Earnings Call Boost, Tesla Tailwinds: Retail Turns Optimistic</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

These 3 stocks have generated the most bullish sentiment among retailers Thursday afternoon.

Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon

A micro-cap, clinical-stage biotech and two battery manufacturers elicited the most bullish reaction from retail traders.

Equity

A micro-cap, clinical-stage biotech and two battery manufacturers elicited the most bullish reaction from retail traders.


Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
read more...

Shares of Monopar Therapeutics, Inc. (<a class="mention" data-mention="$MNPR" data-symbol-id="MNPR" href="https://stocktwits.com/symbol/MNPR" target="_blank">$MNPR</a>) soared over 500% on Thursday following a major licensing agreement with AstraZeneca (<a class="mention" data-mention="$AZN" data-symbol-id="AZN" href="https://stocktwits.com/symbol/AZN" target="_blank">$AZN</a>) unit Alexion.&nbsp;The stock hit its highest levels since March 2021 and became the top gainer across U.S. exchanges, with retail sentiment surging into ‘extremely bullish’ territory.Monopar secured the rights to ALXN-1840, an oral treatment for Wilson’s disease, a rare genetic disorder that leads to toxic copper build-up in organs.&nbsp;The company will be responsible for all future global development and commercialization activities.In exchange, Monopar will pay an upfront sum in cash and equity, along with future royalties and milestone payments.&nbsp;Under Alexion’s prior development, ALXN-1840 had already met its primary endpoint in a Phase 3 clinical trial.On Stocktwits, retail sentiment for MNPR jumped to ‘extremely bullish’ (97/100), the highest score this year, driven by a surge in message volume as investors reacted to the breakthrough deal.&nbsp;<stembedurl>https://stocktwits.com/Krystian_v/message/589991504</stembedurl><stembedurl>https://stocktwits.com/Mosconi/message/589994892</stembedurl>Monpar stated that its MD, Co-Founder, and CEO, Chandler Robinson, previously conducted laboratory research on tetrathiomolybdate, published his findings in Science, and helped launch the company behind what became ALXN-1840. The focus was on Wilson disease.Wilson’s disease affects around 1 in 30,000 people in the U.S., causing excess copper to accumulate in the liver, brain, and other organs.&nbsp;The disease can lead to liver failure, neurological symptoms, and psychiatric issues, with many cases suffering irreversible damage.MNPR stock has now surged over 1,500% year-to-date.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/lilm-stock-crashes-after-insolvency-warning/cJ21sAxR7k">Air-Taxi Firm Lilium’s Stock Nosedives On Insolvency Warning: Retail Mood Darkens</a>

Monopar secured the rights to ALXN-1840, an oral treatment for Wilson’s disease, a rare genetic disorder that leads to toxic copper build-up in organs.

Monopar Stock Skyrockets After Agreement With AstraZeneca's Unit On Wilson's Disease Drug: Retail On Cloud Nine

The company will be responsible for all future global development and commercialization activities.

Monopar Stock Skyrockets After Agreement With AstraZeneca’s Unit On Wilson's Disease Drug: Retail On Cloud Nine

The company will be responsible for all future global development and commercialization activities.


Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today

Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
read more...

Monopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical Data

JonesTrading analyst Justin Walsh reiterated a Buy rating on Monopar Therapeutics Inc (MNPR Research Report) today and set a price target of $2.0...

Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial

The latest announcement is out from Monopar Therapeutics Inc (MNPR). Monopar Therapeutics Inc. has reached a pivotal milestone by enrolling the fir...

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.41	--	--	N/A
Q2 '25	-$0.43	-$0.35	19.23%	BEAT
Q1 '25	-$0.47	-$0.38	19.15%	BEAT
Q4 '24	-$0.74	-$2.74	-271.53%	MISSED
Q3 '24	-$0.92	-$0.37	59.56%	BEAT

MNPR
Monopar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest MNPR News

MNPR Monopar Therapeutics Inc